# A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Source: https://onco.cc/trials/nct05989542/  
OnCo record `nct05989542` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company in non-small-cell lung cancer and small-cell lung cancer, now recruiting.

## Summary

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is a phase 3 interventional study registered as NCT05989542 by Beijing Pearl Biotechnology Limited Liability Company, with 136 participants planned, started 2023-10-16. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: KUNPENG-2
- Tags: ctgov-ingest
- Registry id: NCT05989542
- Phase: 3
- Setting: An Open, Multi-center, Single-arm Phase IIIb Confirmatory Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vebreltinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Exon 14 Mutation
- Sponsor: Beijing Pearl Biotechnology Limited Liability Company
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT05989542: https://clinicaltrials.gov/study/NCT05989542

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- companies: [Beijing Pearl Biotechnology Limited Liability Company](https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/)

---
JSON: https://onco.cc/api/v1/entities/nct05989542.json